Literature DB >> 9584168

GATA-1 dominantly activates a program of erythroid gene expression in factor-dependent myeloid FDCW2 cells.

D Seshasayee1, P Gaines, D M Wojchowski.   

Abstract

Erythrocyte development has previously been shown to depend upon the expression of the lineage-restricted trans-acting factor GATA-1. Despite predicted roles for this factor during early development, GATA-1-deficient cells in chimeric mice and embryonic stem cell cultures mature to a late proerythroblast stage and express at least certain genes that normally are thought to be regulated by GATA-1 (including erythroid Krüppel-like factor [EKLF] and the erythropoietin [Epo] receptor). Opportunities to test roles for GATA-1 in erythroid gene activation in these systems therefore are limited. In the present study, in an alternate approach to test the function of GATA-1, GATA-1 has been expressed together with the Epo receptor in myeloid FDCW2 cells and the resulting effects on cytokine-dependent proliferation and erythroid gene expression have been assessed. GATA-1 expression at low levels delayed FDCW2ER cell cycle progression at the G1 phase specifically during Epo-induced mitogenesis. Upon expression of GATA-1 at increased levels, proliferation in response to Epo, interleukin-3 (IL-3), and stem cell factor was attenuated and endogenous GATA-1, EKLF and betamaj-globin gene expression was activated. Friend of GATA-1 (FOG) transcript levels also were enhanced, and ets-1 and c-mpl but not Epo receptor gene expression was induced. Finally, in FDCW2 cells expressing increased levels of GATA-1 and a carboxyl-terminally truncated Epo receptor, Epo (with respect to IL-3 as a control) was shown to markedly promote globin transcript expression. Thus, novel evidence for select hierarchical roles for GATA-1 and Epo in erythroid lineage specification is provided.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584168      PMCID: PMC108909          DOI: 10.1128/MCB.18.6.3278

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

1.  Epo-induced hemoglobinization of SKT6 cells is mediated by minimal cytoplasmic domains of the Epo or prolactin receptors without modulation of GATA-1 or EKLF.

Authors:  T T Reese; R C Gregory; E R Sharlow; R E Pacifici; J A Crouse; K Todokoro; D M Wojchowski
Journal:  Growth Factors       Date:  1997       Impact factor: 2.511

2.  FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.

Authors:  D K Watson; L Robinson; D R Hodge; I Kola; T S Papas; A Seth
Journal:  Oncogene       Date:  1997-01-16       Impact factor: 9.867

3.  Erythroid Krüppel-like factor exhibits an early and sequentially localized pattern of expression during mammalian erythroid ontogeny.

Authors:  C M Southwood; K M Downs; J J Bieker
Journal:  Dev Dyn       Date:  1996-07       Impact factor: 3.780

4.  A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.

Authors:  R A Shivdasani; Y Fujiwara; M A McDevitt; S H Orkin
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation.

Authors:  A P Tsang; J E Visvader; C A Turner; Y Fujiwara; C Yu; M J Weiss; M Crossley; S H Orkin
Journal:  Cell       Date:  1997-07-11       Impact factor: 41.582

6.  GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm.

Authors:  E E Morrisey; H S Ip; M M Lu; M S Parmacek
Journal:  Dev Biol       Date:  1996-07-10       Impact factor: 3.582

7.  Transcription factor GATA-3 is required for development of the T-cell lineage.

Authors:  C N Ting; M C Olson; K P Barton; J M Leiden
Journal:  Nature       Date:  1996-12-05       Impact factor: 49.962

8.  Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain.

Authors:  B Joneja; D M Wojchowski
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

9.  GATA-5: a transcriptional activator expressed in a novel temporally and spatially-restricted pattern during embryonic development.

Authors:  E E Morrisey; H S Ip; Z Tang; M M Lu; M S Parmacek
Journal:  Dev Biol       Date:  1997-03-01       Impact factor: 3.582

10.  Constitutive expression of GATA-1 interferes with the cell-cycle regulation.

Authors:  A Dubart; P H Roméo; W Vainchenker; D Dumenil
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

View more
  6 in total

1.  Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells.

Authors:  Clare Heyworth; Stella Pearson; Gillian May; Tariq Enver
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

Review 2.  Hematopoiesis and T-cell specification as a model developmental system.

Authors:  Ellen V Rothenberg; Hao Yuan Kueh; Mary A Yui; Jingli A Zhang
Journal:  Immunol Rev       Date:  2016-05       Impact factor: 12.988

3.  Induction of megakaryocytic differentiation in primary human erythroblasts: a physiological basis for leukemic lineage plasticity.

Authors:  A N Goldfarb; D Wong; F K Racke
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  GATA-1-mediated proliferation arrest during erythroid maturation.

Authors:  Marcin Rylski; John J Welch; Ying-Yu Chen; Danielle L Letting; J Alan Diehl; Lewis A Chodosh; Gerd A Blobel; Mitchell J Weiss
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

Review 5.  Hematopoietic Stem Cells: Nature and Niche Nurture.

Authors:  Geoffrey Brown
Journal:  Bioengineering (Basel)       Date:  2021-05-15

6.  Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage.

Authors:  Alan B Cantor; Hiromi Iwasaki; Yojiro Arinobu; Tyler B Moran; Hirokazu Shigematsu; Matthew R Sullivan; Koichi Akashi; Stuart H Orkin
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.